ThromboGenics’ Jetrea Clears Advisory Committee On Strength Of Unmet Need
Executive Summary
FDA urged consideration of additional pre-market safety studies for the vitreomacular adhesion product, but desire for an additional treatment option for a condition that at present is treated only with surgery overrode potential concerns about visual acuity side effects.